New Effort to Develop Molecular Tools for Early Cancer Detection Under Way

摘要

Despite its promise, the field of clinical proteomics is still in its infancy, and is likely to face the usual unexpected setbacks and dead-ends that scientists encounter when breaking new ground. For example, researchers must sift through thousands of proteins to find clinically useful biomarkers."You have to look at this as a funnel" through which many candidate biomarkers enter but relatively few emerge, said Martin Mclntosh, PhD, coprincipal investigator of the consortium and a cancer researcher at Fred Hutchinson Cancer Research Center. He said the process will likely be slow.